IL-17A in psoriatic arthritis: mechanistic insights, clinical implications, and advances in therapeutic strategies

被引：0

作者：

Caso, Francesco ^{[1
]}

Saviano, Anella ^{[2
]}

Marigliano, Noemi ^{[2
]}

Casillo, Gian Marco ^{[3
]}

Peluso, Michele ^{[4
]}

Ciccone, Miriam ^{[5
]}

Serao Creazzola, Simona ^{[5
]}

D'Agostino, Teresa ^{[6
]}

Mansour, Adel Abo ^{[7
]}

Tasso, Marco ^{[1
]}

Cascone, Mario ^{[1
]}

Megna, Matteo ^{[8
]}

Iqbal, Asif Jilani ^{[9
]}

Scarpa, Raffaele ^{[1
]}

Costa, Luisa ^{[1
]}

Maione, Francesco ^{[2
]}

机构：

[1] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

[2] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, ImmunoPharmaLab, Naples, Italy

[3] AORN A Cardarelli, Pharm Unit, Naples, Italy

[4] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, Naples, Italy

[5] ASL Napoli 1 Ctr, UOC Farmaceut Convenzionata & Terr, Naples, Italy

[6] UOSD Farm Ariano Irpino, Avellino, Italy

[7] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia

[8] Univ Naples Federico II, Dept Clin Med & Surg, Dermatol Unit, Naples, Italy

[9] Univ Birmingham, Coll Med & Hlth, Sch Med Sci, Dept Cardiovasc Sci, Birmingham, England

来源：

EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2025年

关键词：

IL-17; inflammation; psoriatic arthritis; Th17; secukinumab; ixekizumab; bimekizumab; brodalumab; FIBROBLAST-LIKE SYNOVIOCYTES; PREVIOUS INADEQUATE RESPONSE; RESOLVING LIPID MEDIATORS; MAST-CELLS CONTRIBUTE; QUALITY-OF-LIFE; DOUBLE-BLIND; DISEASE-ACTIVITY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; TNF-ALPHA;

D O I：

10.1080/1744666X.2025.2522950

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

IntroductionPsoriatic arthritis (PsA) is an immune-inflammatory disease involving skin and synovial-entheseal compartments. The understanding of IL-17 biological function has revolutionized the understanding of PsA pathogenesis and, consequently, its therapeutic approach.Areas coveredIn this review article, we have outlined the primary evidence regarding the biological functions of IL-17A in PsA, and summarized data from randomized controlled trials (RCTs) on PsA and psoriasis approved secukinumab, ixekizumab, bimekizumab, brodalumab, and emerging IL-17 inhibitors.Expert opinionThe biologic disease-modifying antirheumatic drugs (bDMARDs), secukinumab, and ixekizumab target interleukin-17A (IL-17A), and bimekizumab, which simultaneously neutralizes IL-17A and IL-17F, have demonstrated efficacy in treating both peripheral and axial articular manifestations of PsA, as well in improving skin involvement, enthesitis and dactylitis. Brodalumab, which inhibits the IL-17 receptor A (IL-17RA), represent an efficacious strategy for psoriasis.Continued research into the role of IL-17s in PsA pathogenesis is crucial for improving our understanding of the disease and developing more effective therapeutic strategies. Further research and advancements in biologic therapies will refine IL-17 inhibitory strategies, potentially improving outcomes for PsA patients, and other immune-mediated diseases.Expert opinionThe biologic disease-modifying antirheumatic drugs (bDMARDs), secukinumab, and ixekizumab target interleukin-17A (IL-17A), and bimekizumab, which simultaneously neutralizes IL-17A and IL-17F, have demonstrated efficacy in treating both peripheral and axial articular manifestations of PsA, as well in improving skin involvement, enthesitis and dactylitis. Brodalumab, which inhibits the IL-17 receptor A (IL-17RA), represent an efficacious strategy for psoriasis.Continued research into the role of IL-17s in PsA pathogenesis is crucial for improving our understanding of the disease and developing more effective therapeutic strategies. Further research and advancements in biologic therapies will refine IL-17 inhibitory strategies, potentially improving outcomes for PsA patients, and other immune-mediated diseases.

引用

页数：17

共 186 条

[1] Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis [J].